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PCoronary Artery Disease
he Effects of Plasma Insulin and
lucose on Myocardial Blood Flow in
atients With Type 1 Diabetes Mellitus
uthayyah Srinivasan, MBBS, MS,* Pilar Herrero, MS,† Janet B. McGill, MD,‡ Jasper Bennik, MD,†
astiaan Heere, MD,† Donna Lesniak, RN,† Victor G. Davila-Roman, MD,* Robert J. Gropler, MD*†
t. Louis, Missouri
OBJECTIVES The objective of this study was to determine the impact of insulin and glucose on myocardial
vasodilator function in patients with type 1 diabetes mellitus (T1DM).
BACKGROUND The relative importance of plasma insulin and glucose levels on the abnormal vasodilator
function observed in T1DM is unknown.
METHODS Twenty T1DM patients underwent positron emission tomography studies to measure
myocardial blood flow (MBF) (in ml/g/min) at rest (MBFr) and during adenosine (MBFa),
both under baseline metabolic conditions and then during either hyperinsulinemic-
euglycemic clamp (HE) (n  10; 40  9 years, 8 female subjects, hemoglobin A1c [HbA1c]
7.8  1.1%) or hyperinsulinemic-hyperglycemic clamp (HH) (n  10; 44  12 years, 8
female subjects, hemoglobin A1c 7.7  0.6%).
RESULTS Both groups showed similar MBFr and MBFa under baseline metabolic conditions (pNS).
Compared with baseline conditions, MBFr increased in the HH group (p  0.005), whereas
it did not change in the HE group. Compared with baseline conditions, MBFa decreased in
the HH group (p  0.05) but did not change in the HE group. Myocardial perfusion reserve
(MPR) (MBFa /MBFr) was similar between the HE and HH groups at baseline (p  NS).
During clamp, MPR tended to decrease in the HH group (p  0.1) but did not change in
the HE group (p  NS) when compared with baseline conditions. However, during the
clamp MPR was significantly lower in the HH group when compared with the HE group (p
 0.0001).
CONCLUSIONS In the short term, hyperglycemia has a deleterious effect on myocardial vasodilator function,
which outweighs the beneficial effect of hyperinsulinemia. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.05642–8) © 2005 by the American College of Cardiology Foundation
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Tiabetes mellitus afflicts more than 10 million patients in
he U.S. Cardiovascular disease is the leading cause of excess
ortality observed in this population (1). Accelerated ath-
rosclerosis has been well documented (2), but microvascu-
ar and macrovascular dysfunction, autonomic neuropathy,
nd specific structural, functional, and biochemical alter-
tions may contribute to the excess cardiac morbidity and
ortality in diabetes (3). Animal models of diabetes melli-
See page 49
us have shown impairment of both endothelial-dependent
nd endothelial-independent vasodilation (4). Human stud-
es have confirmed the impairment of vasodilator reserve in
he coronary circulation of patients with type 1 diabetes
ellitus (T1DM) and type 2 diabetes mellitus (T2DM) (5).
From the *Cardiovascular Division, Department of Medicine, the †Division of
adiological Sciences, Edward Mallinckrodt Institute of Radiology, and the ‡Divi-
ion of Endocrinology and Metabolism, Department of Medicine, Washington
niversity School of Medicine, St. Louis, Missouri. Supported in part by NIH grants
01-AG15466, P01-HL-13581, K24-HL67002, S10-RR14778, and M01-
R00036, and a grant from the Barnes-Jewish Hospital Foundation to the Cardio-
ascular Imaging and Clinical Research Core Laboratory.a
Manuscript received September 29, 2004; revised manuscript received February 4,
005, accepted March 10, 2005.Type 1 diabetes mellitus by definition requires exogenous
nsulin therapy. Insulin administered either subcutaneously
r intravenously produces peripheral hyperinsulinemia at
evels needed to keep the blood glucose normalized because
f the lack of first-pass hepatic extraction of the hormone.
atients with T1DM also have hyperglycemia for prolonged
eriods of time in the setting of both hyperinsulinemia and
ypoinsulinemia because of mismatched timing of insulin
eaks with food intake or inadequate insulin regimens.
nsulin has known vasodilatory properties that are dose
ependent (6), whereas hyperglycemia impairs vasodilation
7). In animal models of T1DM, acute insulin administra-
ion normalizes coronary artery sensitivity to adenosine (8).
n humans with diabetes, tight glycemic control results in a
1% reduction in risk for the development of cardiovascular
isease (9). Thus, the relative contribution of insulin and
lucose to the vascular dysfunction noted in diabetes mel-
itus is not well understood. Our hypothesis was that in
atients with T1DM, hyperglycemia would have greater
eleterious consequences on myocardial vascular function
han that mitigated by concomitant hyperinsulinemia. Ac-
ordingly, myocardial vasodilator function in patients with
1DM was compared under conditions of hyperinsulinemiand hyperglycemia with hyperinsulinemia and euglycemia.
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atients. Twenty T1DM patients were enrolled who met
he inclusion criteria of a hemoglobin A1c (HbA1c) level of
% to 10%, no active retinopathy nor clinically significant
utonomic neuropathy, serum creatinine of 1.5 mg/dl,
edentary lifestyle, no known cardiac disease, and no other
isk factors for coronary artery disease. The choice of
tudying patients with T1DM instead of patients with
2DM was made to reduce the confounding effects on
yocardial vasodilator function of concomitant obesity,
ypertension, and hyperlipidemia typically present in pa-
ients with T2DM. Non-diabetic controls were not studied
ecause our working hypothesis was that the detrimental
ffects of hyperglycemia on myocardial hyperemia induced
y adenosine would outweigh the potential effects of hyper-
nsulinemia in T1DM patients. All patients had a normal
est/stress echocardiogram at screening. The study was
pproved by the Human Studies and the Radioactive Drug
esearch Committees at Washington University School of
edicine. Written informed consent was obtained from all
atients before enrollment into the study.
tudy protocol. Patients were admitted to the General
linical Research Center at Washington University the
vening before the study for stabilization of metabolic
arameters with an insulin drip at physiologic replacement
oses (1 to 2 U/h) to maintain blood glucose levels of 5 to
mmol/l. Caffeine-containing beverages and theophylline-
ontaining medications were withheld for 24 h before the
tudy. After an overnight fast, studies were performed on a
onventional commercially available tomograph (Siemens
CAT 962 HR, Siemens Medical Systems, Islin, New
ersey). Under these baseline metabolic conditions, myocar-
ial blood flow (MBF) was measured by positron emission
omography with 15O-water (10). The measurements were
btained under resting conditions and then during the
ntravenous infusion of adenosine. In brief, 0.4 mCi/kg of
5O-water was injected as an intravenous bolus and data
ere collected for 300 s. Then adenosine was infused at rate of
.140 mg/kg/min for a total of 7 min. A repeat 15O-water data
ollection was performed during the last 5 min of the infusion.
n completion of the baseline measurements, patients were
andomly assigned to undergo a hyperinsulinemic-euglycemic
Abbreviations and Acronyms
HbA1c  hemoglobin A
HE  hyperinsulinemic-euglycemic clamp
HH  hyperinsulinemic-hyperglycemic clamp
MBF  myocardial blood flow
MBFa  myocardial blood flow during adenosine
MBFr  myocardial blood flow at rest
MPR  myocardial perfusion reserve
RPP  rate-pressure product
T1DM  type 1 diabetes mellitus
T2DM  type 2 diabetes mellituslamp (HE) (n 10; insulin 0.1 U/kg/h with target glucose
D
hf 5 to 7 mmol/l) or a hyperinsulinemic-hyperglycemic
lamp (HH) (n 10; insulin 0.1 U/kg/h with target glucose
f 11 to 14 mmol/l) (11). The clamps were instituted for 90
in, and then the measurements of MBF at rest (MBFr)
nd during adenosine (MBFa) were repeated. Plasma insu-
in and glucose levels were measured throughout the imag-
ng study.
mage analysis. To generate myocardial time-activity
urves, regions of interest encompassing the anterior, lateral,
nferior, and septal walls were placed on three to four
id-ventricular short-axis slices of composite 15O-water
mages as previously described (12). To generate blood
ime-activity curves, for each tracer, a small region of
nterest (1 cm3) was placed within the left atrial cavity on a
id-ventricular slice in the horizontal long-axis orientation
f each composite image. Subsequently, blood and myocar-
ial time-activity curves were used in conjunction with a
ell-established kinetic model to measure MBF (in ml/g/
in) in each myocardial region analyzed and averaged to
btain one value per patient per study for MBFr, MBFa,
nd myocardial perfusion reserve (MPR) (MBFa/MBFr).
tatistical analysis. Differences in plasma insulin, plasma
lucose, MBF, and MPR were analyzed by a three-way
nalysis of variance for repeated measurements, with patient
roups (HE vs. HH) as the grouping factor and clamp (vs.
aseline) and adenosine (vs. rest) as the repeated measure-
ents factors. Subsequent post-hoc tests using the Bonfer-
oni method were performed on those factors, and factor
nteractions with p  0.05 were considered significant.
imilarly, differences in MPR were analyzed by a two-way
nalysis of variance for repeated measurements with patient
roups (HE vs. HH) as the grouping factor and clamp (vs.
aseline) as the repeated measurement factor. Subsequent
ost-hoc tests using the Bonferroni method were per-
ormed. To determine whether glucose blood levels contrib-
ted significantly to the decline in MPR, backward stepwise
egression analysis was performed using MPR measured
uring the clamps as the dependent variable and age,
ender, and HbA1c and plasma insulin and glucose levels
uring the clamps as the independent variables. All average
ata are presented as mean and standard deviation of the
ean.
able 1. Clinical Characteristics
HE Group HH Group
ubjects (#) 10 10
ender (females #) 8 8
ge (yrs) 40  9 44  12
eight (kg) 75  8 76  12
emoglobin A1c (%) 7.8  1.1 7.7  0.6
uration of DM (yrs) 26  10 24  9
holesterol level (mg/dl) 173  28 179  31
DL cholesterol (mg/dl) 96  17 107  38M  diabetes mellitus; HE  hyperinsulinemic-euglycemic clamp; HH 
yperinsulinemic-hyperglycemic clamp; LDL  low-density lipoprotein.
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linical characteristics. The HE and HH groups were
imilar with respect to age, gender composition, duration of
1DM, cholesterol profile, and level of glycemic control
Table 1). All patients were taking insulin for glycemic
ontrol; only one patient was additionally on glucophage.
hree patients in each group were on thyroid sup-
lementation.
lasma substrates and insulin. The plasma insulin levels
nder baseline metabolic conditions were similar in the
roups both at rest (HE, 27.4  8.0 mU/l; HH, 30.5  8.4
U/l; p  NS) and during adenosine (HE, 22.8  5.3
U/l; HH, 20  13.7 mU/l; p  NS) (Fig. 1). Under
lamp conditions, plasma insulin levels were also similar
etween the groups both at rest (HE, 95.8  13.1 mU/l;
H, 100.9  15.3 mU/l; p  NS) and during adenosine
HE, 85.8  11.7 mU/l; HH, 65.2  8.5 mU/l; p  NS).
nsulin levels increased during hyperinsulinemic clamp in
oth groups as expected (p  0.0001) compared with
aseline metabolic conditions. Under baseline metabolic
onditions, plasma glucose levels were similar between the
roups both at rest (HE, 6.4  0.2 mmol/l; HH, 6.1  0.3
mol/l; p  NS) and during adenosine (HE, 6.2  0.2
mol/l; HH, 5.7  0.5 mmol/l; p  NS) (Fig. 2). As
nticipated, plasma glucose levels during clamp conditions
ere higher in the HH group compared with the HE group
oth at rest (13.7  0.7 mmol/l vs. 5.8  0.2 mmol/l, p 
.0001) and during adenosine (12.8  1.0 mmol/l vs. 5.0 
.2 mmol/ml, p  0.0001).
emodynamics. Under baseline and clamp metabolic
onditions, heart rate, systolic blood pressure, diastolic
ressure, and the rate-pressure product were similar
etween the two groups at rest (Table 2). During
denosine, the heart rate increased to a similar level in
oth groups (p  0.0001 compared with rest). Systolic
lood pressure did not change in either group with
denosine. Diastolic blood pressure decreased with aden-
sine similarly in both groups (p  0.0001). Because ofigure 1. Plasma insulin levels under baseline metabolic conditions and during
lamp (HH).he increase in heart rate, the rate-pressure product
RPP) increased to a similar extent in both groups with
denosine (p  0.0001 compared with rest). Similar
atterns were noted at rest and during adenosine in the
lamp groups. There were no differences in the rest or
denosine values between baseline metabolic and clamp
onditions or between the clamp groups.
BF measurements. Under baseline metabolic conditions
oth MBFr (HE, 1.19  0.19 ml/g/min; HH, 1.20  0.24
l/g/min; p  NS) and MBFa (HE, 3.70  0.48 ml/g/
in; HH, 3.05  0.26 ml/g/min; p  NS) were similar
etween the groups (Fig. 3). With institution of the clamp,
he MBFr in the HE group did not change (1.06  0.04
l/g/min, p  NS), although it increased (1.53  0.11
l/g/min, p  0.005) in the HH group compared with
aseline resting conditions. In response to adenosine, no
ignificant differences were noted in MBFa in the HE group
3.99  0.37 ml/g/min) compared with baseline metabolic
onditions (p  NS). However, in the HH group, MBFa
as significantly lower during the clamp (2.81  0.26
l/g/min) when compared with baseline metabolic condi-
ions (p  0.05). The MPR under baseline metabolic
onditions was similar between the HE (3.14  0.40) and
H (2.69  0.41) groups (p  NS) (Fig. 4). Under clamp
onditions, the MPR did not change in the HE group (3.79
0.36, p  NS). In the HH group, the MPR tended to
ecrease with institution of the clamp (1.92 0.21, p 0.1
ompared with baseline metabolic conditions). Moreover,
he MPR in the HH group was significantly lower than that
bserved in the HE group (p  0.001).
mpact of plasma insulin and glucose on MPR. Back-
ard stepwise regression analysis identified plasma glucose
evels and HbA1c as significant negative predictors of MPR
easured during the clamps. Glucose was a stronger pre-
ictor (F  20.3) than HbA1c (F  4.93). Gender (F 
.81 []), plasma insulin (F  0.32 []), and age (F 
.00) were not significant predictors of MPR.hyperinsulinemic-euglycemic (HE) and hyperinsulinemic-hyperglycemic
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he results of this study show that at least in the short term,
yperglycemia negates the salutary effects of hyperinsulin-
mia on myocardial vasodilator function in patients with
1DM. Thus, in patients with T1DM, the presence of
yperglycemia may be a significant contributor to the
evelopment of abnormal myocardial vascular reactivity
bserved in these patients.
asodilator function in diabetes mellitus. Diabetes mel-
itus is associated with a state of endothelial dysfunction
13) in both animal models (14) and human tissue (15),
esulting in impaired myocardial vasodilatory reserve (5).
he values for MPR obtained under baseline metabolic
onditions (Fig. 4) are lower than those reported for healthy
ndividuals without diabetes mellitus (16–18), suggesting
hat vasodilator function was reduced in our patients.
ossible mechanisms for the impairment in vasodilatory
eserve include effects of reduced capillary surface density,
utonomic neuropathy, hyperlipidemia, hyperglycemia, and
ypoinsulinemia (13,19–22).
ffects of glucose. Potential mechanisms mediating the
etrimental effects of hyperglycemia on vascular function
nclude oxidative stress, reduced nitric oxide production,
nd an increase in vasoconstrictive prostanoids (7). Under
igure 2. Plasma glucose levels under baseline metabolic conditions and d
lamp (HH).
able 2. Hemodynamics During Study
Group Heart Rate (beats/min)
est HE 73  4
HH 72  3
denosine* HE 100  3
HH 103  4
lamp HE 76  5
HH 83  5
lamp adenosine* HE 98  3
HH 111  4
p  0.0001 effect of adenosine vs. respective rest conditions (baseline metabolic or
DBP  diastolic blood pressure; HE  hyperinsulinemic-euglycemic clamp; HH  hy
lood pressure.yperglycemic conditions, as much as one-third of the
etabolism of glucose is shunted through the polyol path-
ay. Increased activity of the polyol pathway leads to
xidative stress by virtue of the fact that aldose activity
equires and may deplete nicotine-adenine dinucleotide
hosphate. Free-radical scavengers such as superoxide dis-
utase (23) and aldose reductase inhibitors (24) reverse the
ffects of hyperglycemia on vascular responsiveness. Many
nzymes, including nitric oxide synthase, the enzyme re-
ponsible for the generation of endothelial-dependent re-
axing factor, nitric oxide, require reduced nicotine-adenine
inucleotide phosphate. The nitric oxide-mediated compo-
ent of acetylcholine-induced relaxation is impaired in
treptozotocin diabetic rats (25). Hyperglycemia also leads
o increased production of endothelial vasoconstrictor pro-
tanoids, especially prostaglandin H2, and this can impair
he acetylcholine-mediated vasodilator response (26). Cul-
ured porcine aortic cells exposed to elevated glucose levels
roduce significantly more prostaglandins when stimulated
ith bradykinin (27). Increased prostanoid production is
ediated by protein kinase C activation, and effects on
asoconstriction might be mediated by free radicals (26).
inally, when plasma and cell membrane proteins are
xposed to chronic high glucose concentrations, they un-
hyperinsulinemic-euglycemic (HE) and hyperinsulinemic-hyperglycemic
SBP (mm Hg) DBP (mm Hg) RPP (mm Hg/min)
114  5 67  2 6,006  392
129  7 74  2 6,686  369
118  4 64  2 8,162  294
115  6 61  3 8,204  648
121  7 69  2 6,569  398
126  6 71  2 7,440  487
123  4 62  3 8,069  331
124  5 63  3 9,469  634
) for HR, DBP, and RPP.clamp
perinsulinemic-hyperglycemic clamp; RPP  rate-pressure product; SBP  systolic
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esultant advanced glycosylation end products can inhibit
itric oxide (28).
The results of this study confirm these observations in
umans with T1DM. Indeed, our results are consistent with
esults of studies in patients with either T1DM or T2DM,
n which hyperglycemia has been shown to be an indepen-
ent predictor of abnormal myocardial vasodilator function
29,30). Of note, Sundell et al. (31) performed a similar type
f study but observed that hyperglycemia in the setting of
yperinsulinemia did not reduce MPR in patients with
1DM. However, they exclusively studied men with a mean
ge of 33 years, whereas our population was 80% female
ith a mean age of 44 years (Table 1). Our population had
1DM for a longer duration, and was sedentary. To our
nowledge there is no information about gender or age
igure 3. Myocardial blood flow (MBF) under baseline metabolic cond
yperglycemic clamp (HH). AD  adenosine infusion.igure 4. Myocardial perfusion reserve (MPR) under baseline metabolic conditi
yperglycemic clamp (HH).ifferences in myocardial vasodilator capacity in diabetes
ellitus, particularly as a function of plasma glucose levels.
owever, it is becoming increasingly apparent that both the
ncidence and the manifestations of coronary artery disease
re more pronounced in female patients with diabetes
ellitus compared with their male counterparts (32,33).
lthough requiring further study, an increased sensitivity in
yocardial vasodilator capacity to plasma glucose levels may
artially explain this phenomenon.
ffects of insulin. Insulin is a skeletal muscle vasodilator
hat acts via nitric oxide-dependent mechanisms leading to
n increase in capillary recruitment (34) in both healthy
atients and those with T1DM (35). In rat mesenteric
rteries it has been shown that insulin-mediated vasodila-
ion is blocked by nonsteroidal antiinflammatory agents and
otassium channel antagonists, suggesting that insulin acts
s and during hyperinsulinemic-euglycemic (HE) and hyperinsulinemic-ons and during hyperinsulinemic-euglycemic (HE) and hyperinsulinemic-
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July 5, 2005:42–8 Glucose and Insulin Effects on MBF in Diabetesy cyclooxygenase-dependent mechanisms that involve ac-
ivation of adenosine triphosphate-dependent potassium
hannels to cause vasodilation (36). In alloxan-induced
iabetic sheep, coronary artery sensitivity to adenosine was
ormalized by acute insulin administration, suggesting that
eduction in adenosine’s vasodilator effect was caused by
ypoinsulinemia (8). Recently it has been reported that
nsulin directly affects myocardial perfusion (37) and in-
reases adenosine-stimulated coronary flow in a dose-
ependent manner in healthy middle-aged men (6). Plasma
ree fatty acids have been shown to impair endothelial-
ependent vasodilation (38). Thus, the beneficial effects of
nsulin on myocardial vasodilation may in part be related to
lowering in plasma fatty acid levels that occurs with insulin
dministration. It has been reported that myocardial energy
ransduction is decreased in transgenic models of diabetes
ellitus, most likely because of the increase in myocardial
xygen consumption caused by the overdependence on fatty
cid oxidation (39). Consequently, a further increase in
yocardial oxygen consumption with insulin could lead to
n increase in myocardial blood flow. However, the myo-
ardial oxygen demands did not increase with either clamp
ompared with baseline metabolic conditions (Table 2).
oreover, insulin infusion should shift myocardial substrate
etabolism toward glucose use and improve efficiency, not
ecrease it. Thus, it is unlikely that alterations in myocardial
nergy transduction were responsible for the observed
hanges in MBF with insulin in the current study.
It should be noted that during the clamps, plasma insulin
evels were lower during adenosine administration (Fig. 1).
lthough the insulin levels during adenosine were on
verage lower in the HH group than in the HE group, the
ifference was not statistically significant. The decline in
lasma insulin levels during adenosine administration likely
eflects the potentiation of insulin-stimulated glucose trans-
ort in adipose tissue, cardiac muscle, and possibly skeletal
uscle (40). However, the multivariable analysis suggests
hat any decrease in plasma insulin had little impact on
yocardial vasodilator function because only plasma glucose
evels and HbA1c levels were significant predictors of the
ifference in MPR observed during the clamp studies.
Adenosine-induced myocardial vasodilation is mediated
y both endothelial-dependent and -independent mecha-
isms, and has been used as an integrated measure of
oronary reactivity (6). The results of this study suggest that
he effects of insulin on adenosine-induced hyperemia are
ess pronounced in patients with T1DM (Fig. 3) and are
ounteracted by the effects of hyperglycemia. This is in
ontrast to results of the study performed by Sundell et al.
31), in which insulin significantly increased hyperemic
lood flow and MPR in patients with T1DM. The reasons
or these differences are unclear, although, as mentioned
bove, gender differences could potentially be contributory.
tudy limitations. The impairment in vasodilator reserve
aused by acute elevations in glucose might not mechanis-
ically reflect the impairments noted with chronic elevations sn glucose observed in the diabetic state. Although we
tudied patients with T1DM, the relevance of these findings
n those with T2DM remains to be defined. Diabetic
utonomic neuropathy is associated with impaired coronary
asodilator response to sympathetic stimulation, which is
elated to the degree of sympathetic dysfunction (41).
lthough 20% to 40% of patients with diabetes show
bnormal autonomic function by clinical testing, even in the
bsence of apparent autonomic neuropathy many have
lterations in cardiac sympathetic pathways as determined
y myocardial scintigraphy. Testing for autonomic dysfunc-
ion was not performed; however, none of the patients had
ignificant peripheral neuropathy or clinically apparent au-
onomic neuropathy. The increase by30 beats/min during
denosine administration (Table 2) is higher than what is
ypically observed with conventional vasodilator stress per-
usion imaging with this drug. The reason for the higher
eart rate is not clear. For example, women have a greater
eflex tachycardia than do men in during adenosine infu-
ion. However, patients with diabetes mellitus have an
ttenuated heart rate response (42). Regardless, there were
o differences in the heart rate levels during adenosine at
aseline or during the clamp intervention between the two
lamp groups.
linical implications. It is possible that attenuation of
oronary vasodilation by hyperglycemia during periods of
ncreased myocardial demand leads to repeated episodes of
yocardial ischemia. Indeed, the value for MPR in the HH
roup (1.92  0.21) is nearly identical to the positron
mission tomography-measured MPR values in myocar-
ium subtended by coronary arteries with 75% diameter
tenosis (1.9 0.7) (18). The relationship between coronary
icrovascular dysfunction and diabetic cardiomyopathy is
upported by observation of similar microvascular abnor-
alities in both diabetes and dilated cardiomyopathy (4).
ndothelial dysfunction not only precedes and predicts
linical macrovascular disease, but also is an independent
rognostic marker of adverse long-term cardiovascular out-
omes (43). The results provide a partial explanation for the
alutary effects of tight glycemic control on reducing the
ncidence and severity of cardiac complications in patients
ith T1DM (9). Identifying the mechanisms by which
yperglycemia leads to impaired vasodilatory capacity and
etermining strategies to prevent it from occurring may
rovide adjunctive therapy for diabetic patients, in whom
ontrol of hyperglycemia is elusive. Such therapy instituted
arly enough may have the potential to prevent or reduce the
anifestations of atherosclerosis and delay diabetes-
ssociated cardiomyopathy.
eprint requests and correspondence: Dr. Robert J. Gropler,
ardiovascular Imaging Laboratory, Mallinckrodt Institute of
adiology, 510 South Kingshighway Boulevard, St. Louis, Mis-ouri 63110. E-mail: groplerr@mir.wustl.edu.
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